SUPPLEMENTARY MATERIALS

Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell lung cancer

Howard West, MD; Xiaohan Hu, PhD; Su Zhang, PhD; Yan Song, PhD; Diana Chirovsky, PhD; Chi Gao, ScD; Ari Lerner, BS; Anya Jiang, MPH; James Signorovitch, PhD; Ayman Samkari, MD

SUPPLEMENTARY FIGURE 1 Study Design

SUPPLEMENTARY FIGURE 2 Overall Survival Stratified by Recurrence Status after 1, 3, or 5 Years Following Surgery
SUPPLEMENTARY FIGURE 1 Study Design

Index date:
Patient with recurrence: 30 days before indication of recurrence
Patient without recurrence: randomly attributed, based on the distribution of time between end of treatment and recurrence for patients in the recurrence cohort

End of study period:
Earliest of end of data availability or end of Medicare Part A, B or D eligibility

Start of study period
Baseline period (12 months):
• Evaluation of patient demographic and clinical characteristics

Observation period (≥ 6 months of continuous eligibility after index date):
• Comparison of clinical outcome and economic burden for patient with vs. without recurrence
SUPPLEMENTARY FIGURE 2 Overall Survival Stratified by Recurrence Status After 1, 3, or 5 Years Following Surgery